The multicompendial API designated GLIMEPIRIDE Micronized IP/USP/EP/BP Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is released against current monographs of the Indian Pharmacopoeia, United States Pharmacopeia, European Pharmacopoeia, and British Pharmacopoeia. The API is identified chemically as glimepiride, CAS 93479-97-1, with molecular formula C₂₄H₃₄N₄O₅S and molecular weight 490.62 g/mol. Micronization is applied to reduce primary particle size for dissolution-limited absorption, because glimepiride behaves as a low-aqueous-solubility, weakly acidic sulfonylurea with pH-dependent dissolution. The grade is intended for dry blending, wet or dry granulation, capsule filling, and direct compression. If an injectable presentation is pursued, the API is not designated sterile by the manufacturer and must undergo further processing to meet parenteral requirements. Compared with unmicronized powder of the same chemical entity, the micronized material shows a larger specific surface area, lower bulk density, and greater electrostatic charge retention. These properties require process controls during dispensing, sieving, and blending to avoid segregation, dusting, and loss of blend uniformity. Polymorphic identity is controlled by X-ray powder diffraction against the current compendial reference standard, and residual solvent content is controlled according to ICH Q3C with the methods of USP <467> and Ph. Eur. 5.4.

Compendial Identity and Assay Alignment Across Four Pharmacopoeias

Identity is confirmed by infrared absorption spectrophotometry and by retention time agreement in the liquid chromatographic assay. The assay acceptance range in current monographs is generally 98.0–102.0% on the dried basis; a multicompendial release protocol may apply a tighter manufacturer range of 99.0–101.0% to ensure that every lot remains within all four pharmacopoeial limits. Related substances are determined by HPLC under the conditions of USP <621> and Ph. Eur. 2.2.29; typical control thresholds limit individual specified impurities to not more than 0.10% and total impurities to not more than 0.5%, although the current monograph should be consulted for compound-specific impurity factors. Loss on drying is measured by USP <731> or Ph. Eur. 2.2.32, and water content by USP <921> or Ph. Eur. 2.5.12. Sulfated ash is controlled by USP <281> or Ph. Eur. 2.4.14. Residual solvents are limited to the class 2 and class 3 options of ICH Q3C, with benzene, carbon tetrachloride, and 1,2-dichloroethane typically excluded or controlled at the parts per million limits given in the relevant monograph. Elemental impurities are controlled under USP <232>, Ph. Eur. 5.20, and ICH Q3D.

In low-dose solid oral dosage forms containing 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, or 8 mg of glimepiride per unit, the API fraction is often below 5% of total tablet weight. At this concentration, the critical process risk is not chemical degradation but physical segregation and poor content uniformity. Micronized glimepiride adheres to blender surfaces and charge-sensitive excipients. On a 600 L bin blender, colloidal silicon dioxide at 0.1–0.5% and a blending time of 15–25 minutes reduce electrostatic agglomeration but can increase the risk of over-lubrication if magnesium stearate is added too early. Content uniformity is assessed by USP <905> or Ph. Eur. 2.9.40; for low-dose tablets, acceptance values below 15 are generally required for the finished dosage form. Segregation during compression is minimised by matching the particle size distribution of the glimepiride with that of the filler, typically lactose monohydrate or dibasic calcium phosphate dihydrate.

Does Micronized Particle Size Distribution Shift During High-Shear Granulation?

Micronized glimepiride with a laser diffraction D90 of 10 µm or less does not necessarily retain that distribution after wet granulation. In high-shear mixers operating with an impeller tip speed of 5–10 m/s and a chopper speed of 1500–3000 rpm, binder addition rate determines agglomerate size. Rapid addition of aqueous binder can produce wet agglomerates above 500 µm, while slow addition with high chopper speed may generate granules with a D50 of 80–150 µm after wet milling and drying. The performance of the final tablet is governed less by the API particle size after granulation than by granule porosity, binder type, and the extent of glimepiride dissolution within the granule liquid bridges. Dissolution testing according to USP <711> or Ph. Eur. 2.9.3 should be used to confirm that the granulation route does not retard release in the chosen medium. For hydrophobic glimepiride, sodium lauryl sulfate at 0.1–0.5% in the dissolution medium or formulation may be required to obtain discriminatory release data.

When Aqueous Granulation Is Avoided Due to Hydrolytic Degradation Risk

The sulfonylurea group in glimepiride is susceptible to hydrolytic cleavage under acidic and strongly alkaline conditions, and this risk increases when aqueous granulation is performed above 60 °C. Aqueous granulation is therefore avoided or strictly controlled in formulation development. Non-aqueous granulation with ethanol or isopropanol, or dry granulation by roller compaction, is preferred when related substances rise above 0.2% during wet massing. Drying after aqueous granulation should achieve a final granule moisture content below 2.0%, with inlet air temperature in a fluid-bed dryer held between 50 °C and 60 °C and exhaust temperature monitored at 30–35 °C. Batch-to-batch variation in related substances can be attributed to residual water in the granule rather than to API instability alone; therefore, the drying endpoint should be correlated with loss on drying by USP <731> or Ph. Eur. 2.2.32 and not solely with exhaust temperature. When roller compaction is used, ribbon density is controlled between 0.9 g/cm³ and 1.1 g/cm³, and the milled granule is screened through an 800 µm sieve to prevent oversized granules from causing weight variation.

The term injectable does not correspond to a dedicated sterile grade in current glimepiride monographs. A formulation intended for parenteral administration must be prepared from the same multicompendial API but must additionally meet the end-product requirements for sterility, bacterial endotoxins, particulate matter, and container closure integrity. Sterility testing is performed under USP <71> or Ph. Eur. 2.6.1. Bacterial endotoxins are controlled by USP <85> or Ph. Eur. 2.6.14, with a limit that is dose-dependent and typically not above 0.5 EU/mg for parenteral products. Particulate matter in the finished injection is assessed by USP <788> or Ph. Eur. 2.9.19; the micronized API itself is not expected to meet these limits before terminal sterilisation or aseptic compounding. Because glimepiride exhibits low aqueous solubility at neutral pH, injectable formulation work generally requires pH adjustment above 7.5, co-solvent addition, or complexation. Published data for this specific configuration is limited, and each formulation must be validated for chemical and physical stability under ICH Q1A storage conditions.

Blend Uniformity Is Governed by Particle Size Overlap and Electrostatic Charging

Direct compression of micronized glimepiride is possible only when the API is first ordered mixed with a suitable carrier to reduce the cohesive forces created by high surface area. The flow function coefficient of the API is low. Bulk density and tapped density measured by USP <616> or Ph. Eur. 2.9.34 typically show a Carr index above 30, indicating poor flow and the need for a glidant. Roller compaction is often used instead of direct compression because it converts low-density micronized powder into dense ribbons and then into granules with improved flow. The main failure mode on tablet presses is sticking to punch faces when granule moisture exceeds 2.5% or when lubricant level is below 0.5%. Magnesium stearate at 0.5–1.0% reduces ejection force, but excessive mixing time with magnesium stearate can retard dissolution of low-solubility glimepiride. The lubricated blend is typically mixed for 3–5 minutes after the final excipient addition, and tablet hardness is monitored to remain within 40–80 N for immediate-release formulations to avoid disintegration delay. Disintegration is assessed by USP <701> or Ph. Eur. 2.9.1, and dissolution is assessed by USP <711> or Ph. Eur. 2.9.3.

Compared with unmicronized glimepiride, the micronized multicompendial grade presents a narrower particle size distribution by laser diffraction and a larger specific surface area, which can increase dissolution rate but also increases sensitivity to moisture and electrostatic charge. A single-compendial grade may be acceptable for a given market, but the multicompendial release protocol eliminates the need for separate qualification when submissions span jurisdictions recognising IP, USP, EP, or BP monographs. Differences from other sulfonylurea APIs such as glibenclamide or gliclazide are primarily pharmacological and formulational: glimepiride is used at lower unit doses and is often formulated with a low API fraction, whereas higher-dose sulfonylureas present different blend uniformity and dissolution challenges. The micronized product is not a co-processed excipient system; it is the pure API with particle size reduction and compendial compliance, and it does not provide built-in stabilisation against hydrolysis or electrostatic charging. Any downstream formulation using this API must therefore be developed with the same process controls as would apply to any micronized, low-solubility, dissolution-limited active substance.